GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Additional Paid-In Capital

Omeros (FRA:3O8) Additional Paid-In Capital : €652.54 Mil(As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Additional Paid-In Capital?


Omeros's quarterly additional paid-in capital increased from Mar. 2024 (€661.30 Mil) to Jun. 2024 (€670.35 Mil) but then stayed the same from Jun. 2024 (€670.35 Mil) to Sep. 2024 (€652.54 Mil).

Omeros's annual additional paid-in capital increased from Dec. 2021 (€625.07 Mil) to Dec. 2022 (€680.41 Mil) but then declined from Dec. 2022 (€680.41 Mil) to Dec. 2023 (€667.52 Mil).

Omeros Additional Paid-In Capital Historical Data

The historical data trend for Omeros's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Additional Paid-In Capital Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 562.54 617.57 625.07 680.41 667.52

Omeros Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 683.90 667.52 661.30 670.35 652.54

Omeros Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Omeros Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Omeros's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Additional Paid-In Capital
Comparable Companies
VSTM ALDX PBYI CRMD INMB GOSS SYRS DRTS XOMA ZURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
OMER:USA 0KBU:UK
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Website
https://www.omeros.com
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Headlines

No Headlines